Merck names ex-Amgen exec to run R&D
Yahoo/AP
Amgen Benefits From Affymax Recall
Seeking Alpha
Can JAK Inhibitors Challenge Biologics?
Motley Fool
Amgen's Future Is Brighter Than You Might Think
Motley Fool
Does the Arthritis Market Have Growing Pains?
Motley Fool
Amgen Inc: Today's Featured Drugs Laggard
The Street

